{
  "asset": "AKEEGA (niraparib/abiraterone)",
  "query_terms": [
    "AKEEGA (niraparib/abiraterone)",
    "niraparib/abiraterone",
    "AKEEGA (niraparib",
    "abiraterone)"
  ],
  "returned_unique": 17,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT06392841",
      "title": "Hispanic/Latino and Non-Hispanic BlAck Patients Treated With niRaparib and Abiraterone Acetate Plus Prednisone for Metastatic hOrmone Sensitive Prostate Cancer With Deleterious Homologous recombinatioN Repair Alterations: a Phase II, Open Label studY",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",
        "Deleterious HRR Gene Mutation",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "BRIP1 Gene Mutation",
        "CHEK2 Gene Mutation",
        "FANCA Gene Mutation",
        "PALB2 Gene Mutation",
        "RAD51B Gene Mutation",
        "RAD54L Gene Mutation"
      ],
      "lead_sponsor": "Qian Qin",
      "collaborators": [
        "UT Southwestern Comprehensive Cancer Center",
        "Janssen, LP"
      ],
      "interventions": [
        "Androgen Deprivation Therapy (ADT)",
        "Niraparib/Abiraterone Acetate DAT",
        "Abiraterone Acetate",
        "Prednisone",
        "Docetaxel"
      ],
      "last_update": "2025-10-20",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06392841"
    },
    {
      "nct_id": "NCT06212583",
      "title": "A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Prostate Cancer",
        "Oligometastatic Disease"
      ],
      "lead_sponsor": "University of Maryland, Baltimore",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "niraparib/abiraterone acetate",
        "Stereotactic ablative radiation therapy (SABR)",
        "Androgen deprivation therapy (ADT)"
      ],
      "last_update": "2025-05-01",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06212583"
    },
    {
      "nct_id": "NCT05689021",
      "title": "Phase 2 Study of CJNJ-67652000 (Niraparib/Abiraterone Acetate Fixed-Dose Combination) and Prednisone for Metastatic Castration-Resistant Prostate Cancer Associated With SPOP Mutation With or Without Homologous Recombination Deficiency",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Adenocarcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "lead_sponsor": "Mayo Clinic",
      "collaborators": [],
      "interventions": [
        "Abiraterone Acetate/Niraparib",
        "Biospecimen Collection",
        "Bone Scan",
        "Computed Tomography",
        "Magnetic Resonance Imaging",
        "Prednisone"
      ],
      "last_update": "2026-01-07",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05689021"
    },
    {
      "nct_id": "NCT04577833",
      "title": "An Open-label, Randomized Study to Assess the Relative Bioavailability (BA) and Bioequivalence (BE) of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Niraparib",
        "Abiraterone Acetate (AA)",
        "Prednisone"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04577833"
    },
    {
      "nct_id": "NCT03431350",
      "title": "A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Prostatic Neoplasms, Castration-Resistant"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Niraparib 200 mg",
        "Cetrelimab 240 mg",
        "Cetrelimab 480 mg",
        "Abiraterone acetate 1000 mg",
        "Prednisone 5 mg"
      ],
      "last_update": "2025-12-23",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03431350"
    },
    {
      "nct_id": "NCT04497844",
      "title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Metastatic Castration-sensitive Prostate Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Niraparib",
        "Abiraterone acetate (AA)",
        "Prednisone",
        "Placebo for Niraparib"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04497844"
    },
    {
      "nct_id": "NCT03748641",
      "title": "A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Castration-Resistant Prostatic Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Niraparib",
        "Abiraterone Acetate",
        "Prednisone",
        "Placebo",
        "New Formulation of Niraparib and Abiraterone Acetate (AA)"
      ],
      "last_update": "2025-12-22",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03748641"
    },
    {
      "nct_id": "NCT06329830",
      "title": "Safety and Anti-tumor Activity of Lutetium-177 (177Lu)-PSMA-617 Along With Niraparib and Abiraterone Acetate Plus Prednisone in Metastatic Castration Resistant Prostate Cancer - LUNAAR Study",
      "overall_status": "WITHDRAWN",
      "phase": "Phase 2",
      "conditions": [
        "Metastatic Prostate Cancer",
        "Castration-resistant Prostate Cancer",
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "lead_sponsor": "Baptist Health South Florida",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "177Lu-PSMA-617",
        "Niraparib abiraterone acetate",
        "Prednisone"
      ],
      "last_update": "2024-09-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06329830"
    },
    {
      "nct_id": "NCT03903835",
      "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
      ],
      "lead_sponsor": "Karolinska Institutet",
      "collaborators": [
        "The Swedish Research Council",
        "Kom Op Tegen Kanker",
        "Janssen Pharmaceutica N.V., Belgium",
        "AstraZeneca",
        "Cancerfonden"
      ],
      "interventions": [
        "Enzalutamide Oral Capsule",
        "Abiraterone Oral Tablet",
        "Carboplatin",
        "Cabazitaxel 60 mg Solution for Injection",
        "Docetaxel Injectable Solution",
        "Radium Chloride Ra-223",
        "Niraparib plus Abiraterone acetate plus Prednisone",
        "Capivasertib plus Docetaxel",
        "Apalutamide",
        "Darolutamide"
      ],
      "last_update": "2025-04-09",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
    },
    {
      "nct_id": "NCT04812366",
      "title": "Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Prostate Cancer"
      ],
      "lead_sponsor": "University of British Columbia",
      "collaborators": [
        "Janssen Inc.",
        "University Health Network, Toronto"
      ],
      "interventions": [
        "Apalutamide 60mg Tab",
        "Abiraterone Acetate 250mg",
        "Prednisone 5mg Tab",
        "Docetaxel",
        "Niraparib 100mg Oral Capsule",
        "Atezolizumab"
      ],
      "last_update": "2024-12-16",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04812366"
    }
  ]
}